Immunome, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 227.81K shares, a 299.80% increase year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 38.20K shares, a 85.08% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 7.50K shares, a 96.30% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 68.96K shares, a 61.26% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 389.49K shares, a 49.38% decline from fiscal 2024.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 769.38K shares, a 18.14% increase from fiscal 2023.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 651.24K shares, a 3425.93% increase from fiscal 2022.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 18.47K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 227.81K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 342.46K shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 38.20K shares 10-Q · filed 2026-05-12 | 171.63K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 7.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 389.49K shares 10-K · filed 2026-03-03 |
| 2025-09-30 | 68.96K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 584.83K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 56.98K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 693.86K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 256.06K shares 10-Q · filed 2025-05-12 | 888.33K shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 202.83K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | 769.38K shares 10-K · filed 2025-03-19 |
| 2024-09-30 | 177.99K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | |
| 2024-06-30 | 251.44K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | |
| 2024-03-31 | 137.11K shares 10-Q · filed 2024-05-14 | |
| 2023-12-31 | 651.24K shares 10-K · filed 2024-03-28 | |
| 2022-12-31 | 1.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 18.47K shares 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |